Tarsus Pharmaceuticals, Inc. (TARS) Tops Q1 EPS by 17c

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q1 EPS of ($1.01), $0.17 better than the analyst estimate of ($1.18). Revenue for the quarter came in at $27.61 million versus the consensus estimate of $17.5 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.

You May Also Be Interested In

• Culper Research short Tarsus Pharmaceuticals
• SWBI beats estimates by 71%, GEO nears 52-week high on policy tailwinds
• Tarsus shares fall after short seller report